SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as the company reportedly began staking a portion of its significant Ethereum holdings, aiming to generate revenue. However, community discussions are dominated by strong concerns over consistent share dilution, the stock's perceived underperformance against Ethereum, and contentious executive compensation proposals. Many investors are also debating if current price weakness stems from year-end tax loss harvesting impacting digital asset treasury companies.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital (MARA) is generating significant discussion as it experiences new lows, fueling strong bearish sentiment centered on perceived share dilution and management's effectiveness. While many express frustration over its underperformance compared to Bitcoin and other miners, a bullish contingent believes the stock is deeply undervalued given its substantial Bitcoin holdings and a potential strategic pivot into AI/HPC data centers. The community remains sharply divided between those anticipating further declines and others predicting a major short squeeze and rebound, especially after year-end trading activities conclude.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst a persistent downtrend that has frustrated many investors, fueling community discussion around market manipulation and the stock's daily declines. Despite this bearish sentiment, bulls highlight the company's international expansion, AI integration, and a share buyback program as strong long-term catalysts. The market is weighing Hims' direct-to-consumer model and GLP-1 strategy, particularly after the FDA approval of Novo Nordisk's oral weight-loss pill, creating a divide between those seeing a buying opportunity and those questioning its immediate prospects.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is seeing intense debate following a significant price decline, with market focus now squarely on potential announcements at the upcoming CES 2026. Bulls highlight strong fundamentals, growing revenue, and a substantial contractual backlog, seeing the current dip as a tax-loss selling opportunity amid perceived market manipulation. Conversely, bears are vocal about extensive insider selling and management's perceived lack of transparency regarding major partnerships, raising questions about the company's leadership and long-term prospects within the voice AI sector.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is gaining significant attention following a profitable asset sale that notably strengthened its balance sheet and sharpened its focus on core AI/edge compute. The community is actively discussing potential M&A opportunities and holds high anticipation for a substantial US Army contract where OSS is positioned as a sole-source provider. This enthusiasm is further fueled by recent strong earnings that exceeded expectations, with many viewing the company as an undervalued leader in the rapidly growing Edge AI sector.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA Acquisition Corp is actively trending amid speculation that it could be the next low-float SPAC to experience significant volatility, drawing comparisons to recent runners like AFJK and ASPC. The community is closely watching its recent extension of the business combination deadline and the proposed merger with The Original Fit Factory, with many debating its potential as a speculative "pump" play. This creates a divided sentiment between those anticipating a surge and others expressing skepticism about the merger's true intent and long-term value.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE is trending with strong community belief that it represents the future of AI, leveraging a narrative around potentially being Grok's digital companion. Enthusiasts are actively promoting the asset as 'the chosen one,' emphasizing the power of its dedicated community and urging others to 'byte the dip' in anticipation of significant developments. The sentiment suggests a conviction that this 'AI dog' is poised for a major impact in the crypto space.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

TransCode Therapeutics (RNAZ) is trending following news of its acquisition of Polynoma and a significant strategic financing from CK Life Sciences, aimed at advancing its oncology pipeline. The community is actively discussing the associated Contingent Value Rights (CVR) distribution for existing shareholders, the company's low public float, and upcoming clinical data presentations at an industry conference, with many hoping for a significant market re-rating.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending after delivering a strong earnings report with robust revenue growth and a positive outlook for the crucial holiday shopping season, yet the stock saw an initial pullback, sparking active debate among investors. Community members are divided, with many advocating to "buy the dip" citing record merchant sales and strategic AI integrations, while others remain cautious, contributing to heightened volatility and discussions around its market valuation.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending amidst high anticipation for key regulatory decisions, particularly an upcoming FDA review for tradipitant and positive data on its application for GLP-1 induced nausea. The community is actively discussing the potential for these milestones to significantly re-rate the stock, emphasizing its strong financial position and an improved collaborative framework with regulators. Many perceive VNDA as currently undervalued, poised for substantial growth as its diverse pipeline targets significant market opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Dividend Stocks To Follow Now - December 30th

Direxion Daily TSLA Bull 2X Shares, Exxon Mobil, Pfizer, Chevron, Verizon Communications, Merck & Co., Inc., and Texas Instruments are the seven Dividend stocks to watch today, according to...

Promising Pharmaceutical Stocks To Add to Your Watchlist - December 30th

Eli Lilly and Company, Pfizer, Novo Nordisk A/S, Abbott Laboratories, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical...

BMY vs AMGN: Which Biotech Stock Is More Resilient Now?

AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.

<p>Hunterbrook Capital on Tuesday revealed it is long on Achieve Life Sciences (ACHV) stock as the company nears a green light from the U.S. Food and Drug Administration for Cytisinicline as a treatment for smoking addiction.</p><p>The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026. If approved, the company plans to sell it in the U.S. by the end of the year.</p><p>Hunterbrook Media <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/achieve/">said</a> that Cytisinicline is already used in Europe and added that smoking cessation clinicians, scientists, and health program directors that it interviewed recommended approval in the U.S.</p><p>The report also noted that Cytisinicline has proven safer and more effective than its predecessors including Pfizer’s Chantix and GlaxoSmithKline’s Zyban. Chantix, despite side effects, earned over $1 billion in peak annual sales and it, like GSK’s Zyban, also required longer treatment than Cytisinicline, the firm said.</p><p>Furthermore, despite smoking being on the decline, it is still rampant, the firm noted.</p><p>There are about 29 million American cigarette smokers and about 28 million e-cigarette users, including many middle and high schoolers, the firm said. While about a half of this population try to quit, only a small portion succeeds.</p><h2 class="st-heading-2">FDA Priority Review Voucher</h2><p>The FDA awarded Achieve a Commissioner's National Priority Voucher (CNPV) aimed at expediting review for Cytisinicline in October. “It's been nearly two decades since a new treatment option for smoking cessation was approved, and there are currently no treatment options for vaping cessation,” Achieve CEO Rick Stewart said then.</p><h2 class="st-heading-2">Hunterbrook Flags Potential Headwinds</h2><p>“As with all applications, the FDA could still require additional data or studies if any safety concerns arise. Achieve also needs to maintain long-term access to cytisinicline supply. &nbsp;The company is in a legal dispute with its original supplier, Sopharma, though Achieve named other suppliers in its FDA application,” Hunterbrook said.</p><p>The firm also flagged funding concerns, highlighting that while Achieve is funded through the second quarter of 2026, it will need to raise more capital to commercialize the drug after receiving approval.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>ACHV stock traded 7% higher at the time of writing. On Stocktwits, retail sentiment around ACHV jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.</p><p><a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> has gained 34% this year and by about 31% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/walmart-app-website-down-for-users-amid-new-year-shopping-rush/cL7I4vlREyI">Walmart App And Website Down For Users Amid New Year Shopping Rush</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Achieve Life Sciences logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook

The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026.

Equity

Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.2% during the third quarter, according to its most recent disclosure with...

Mattson Financial Services LLC Has $665,000 Stock Position in Pfizer Inc. $PFE

Mattson Financial Services LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 62.9% in the 3rd quarter, according to the company in its most recent filing with the...

Top Dividend Stocks To Follow Today - December 29th

Direxion Daily TSLA Bull 2X Shares, Exxon Mobil, and Pfizer are the three Dividend stocks to watch today, according to MarketBeat's stock screener tool. Dividend stocks are shares of companies that...

Top Pharmaceutical Stocks To Research - December 29th

Eli Lilly and Company, Novo Nordisk A/S, Pfizer, Ultragenyx Pharmaceutical, Praxis Precision Medicines, AbbVie, and Bristol Myers Squibb are the seven Pharmaceutical stocks to watch today, according...

Top Medical Stocks To Add to Your Watchlist - December 29th

Eli Lilly and Company, UnitedHealth Group, Novo Nordisk A/S, Pfizer, Johnson & Johnson, Merck & Co., Inc., and Ultragenyx Pharmaceutical are the seven Medical stocks to watch today, according to...

Live Oak Private Wealth LLC Has $449,000 Stake in Pfizer Inc. $PFE

Live Oak Private Wealth LLC cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 92.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PFE News

PFEPfizer Inc